The Chronic Oedema Outcome Measure
The Chronic Oedema Outcome Measure (ILF-COM) project is aiming to develop an internationally agreed set of outcome measures for patients with chronic oedema. Here are three of the articles published so far:
Reporting from Parkland Institute Research, Lawson Research Institute, London ON Canada
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and secondary Lymphedema patients
Study preformed in 2018 on how blocking the production of LTB4 in lymphedema patients which could potientally be the first pharmacologic therapy for patients with secondary or primary lymphedema. It can be accessed here.
LIMPRINT (Lymphedema IMpact and PRevalence INTernational; a series of articles published in Lymphatic Research and Biology in 2019)
The primary aim of this large international study was to identify the number of people with chronic edema in nine countries using validated standard methodology. Various articles have been recently published with the results of this large robust study.
LIMPRINT – Acute hospital focus
Dr. Jakub Taradaj (invited speaker of Illuminate Speaker series, University of Manitoba; November 2017)
Scholarly article on the effectiveness of kinesio taping in secondary lymphedema in breast cancer.
Liposuction for Swelling in Patients with Lymphedema
A 2018 article published in the New England Journal of Medicine can be accessed here.